Basking Biosciences Inc

United States - Columbus, OH

• 02/02/2024
• Unknown
• $55,000,000

Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

Related People

Rich SheaFounder

United States - Cary, North Carolina

QUALIFICATIONS SUMMARY
 Senior pharmaceutical industry executive with 25 years of progressive leadership, general management and cross functional professional experience.
 Significant leadership and management experience in all facets of the pharmaceutical industry including commercial operations, product development, and manufacturing.
 Direct experience in a broad range of organizational environments including both entrepreneurial and large, mature organizations.

Specialties: Broad functional management expertise including leadership roles in Sales, Marketing, Finance, Product Development, Alliance Management, Business Strategy, IT and Human Resources

LinkedIn https://www.linkedin.com/in/rich-shea-85a419/